December 5 Product: AstraZenecas Imfinzi Indication: Limited-stage small cell lung cancer AstraZeneca on Wednesday successfully expanded the label of its PD-L1 blocker Imfinzi (durvalumab), notching the FDAs greenlight for its use in patients with limited-stage small cell lung cancer who have not progressed after concurrent platinum chemotherapy and radiation therapy
The skip tier Skip the drug-prescriber funnels and the "GLP-1 booster" hype
What are the most important baby skin care tips for newborns
As reported elsewhere in this document, a guideline needs to be based on both high- or moderate-quantity evidence and consistently demonstrated net medical benefit
With a growing demand for simple, effective wellness solutions, VitaHustle ONE replaces your daily multivitamin with a shake that supports protein intake, mood, energy, gut health, and overall wellness
Gatenby, P., Bhattacharjee, S., Wall, C., Caygill, C